Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Sistemsko zdravljenje z interferoni v onkologiji
Authors:ID Reberšek, Martina (Author)
Files:.pdf PDF - Presentation file, download (157,81 KB)
MD5: E5B80C113F1B35123A7BBFDC190B7A9E
PID: 20.500.12556/dirros/87d90c85-dd0d-48e3-b788-39506a150e31
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:Interferoni so pomembni za komunikacijo med celicami, ki so vključene v obrambo našega imunskega sistema. V onkologiji jih predpisujemo pri zdravljenju različnih rakov, v predpisanih odmerkih. Najpomembnejšo vlogo imajo v adjuvantnem zdravljenju malignega melanoma pri velikih odmerkih z interferonom--α2b tipa. Maligni melanom je v več kot 80 odstotkih ozdravljiva bolezen, če se kirurško odstranjuje v zgodnjih fazah. V primeru pozitivnih regionalnih bezgavk se v več kot polovici teh bolnikov razvije metastatska bolezen, ki je neozdravljiva. Pri bolnikih z večjo verjetnostjo ponovitve bolezni v stadijih IIB, IIC in III se tako priporoča adjuvantna terapija z visokim odmerkom interferona-α2b v Evropi, v stadiju IIIA z visokim tveganjem (velikost metastaze v regionalni bezgavki > 1 mm) in v stadijih IIIB in IIIC pa v ZDA priporočajo zdravljenje z visokim odmerkom anti-CTLA monoklonalnega protitelesa ipilimumaba. Neželeniučinki visokega odmerka interferona so obvladljivi z dobro edukacijo in s sodelovanjem bolnikov.
Keywords:interferoni, sistemsko zdravljenje, onkologija
Publication status:Published
Publication version:Version of Record
Year of publishing:2017
Number of pages:str. 12-14
Numbering:Letn. 21, št. 2
PID:20.500.12556/DiRROS-8192 New window
UDC:616-006
ISSN on article:1408-1741
COBISS.SI-ID:2869115 New window
Copyright:by Authors
Publication date in DiRROS:16.03.2018
Views:4103
Downloads:937
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:16.03.2018

Secondary language

Language:English
Title:Systemic treatment with interferones in oncology
Abstract:Interferons are an integral part of communication between the cells responsible for triggering the protective defenses of our immune system. In oncology, they are administered in prescribed doses to treat different cancers. They are of utmost importance in adjuvant treatment of malignant melanoma, namely in high doses of interferon α2b. Malignant melanoma is a highly aggressive malignant disease that is curable in more than 80 % of patients, if surgically removed in early stages of the disease. If, upon detection, regional lymph nodes are already positive, an incurable metastatic disease develops in more than 50 % of patients. For patients with a greater possibility of disease recurrence (stages IIB, IIC, and III), adjuvant therapy with a high dose of interferon α2b is recommended in Europe; while for high-risk stage IIIA (node metastasis > 1 mm) and stages IIIB and IIIC, a high dose of the anti-CTLA monoclonal antibody ipilimumab is recommended in the United States. The side effects of a high dose of interferon are manageable with a well-educated and compliant patient.


Archive

niGradiv

Back